Background: Soluble interleukin-2 receptor (SIL-2R) is known to be a prognostic parameter in patients with diffuse large B-cell lymphoma (DLBCL) receiving cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy. However, its prognostic value has not been well known since the introduction of rituximab.
introduction Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma [1] . It takes an aggressive clinical course and comprises a heterogeneous group of lymphomas in terms of morphology, phenotype, molecular biology and clinical behavior. Up to now, the International Prognostic Index (IPI) has been the most widely used predictive model for patients with DLBCL treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) [2] . On the other hand, soluble interleukin-2 receptor (SIL-2R) has also been investigated as a prognostic factor, and several studies have demonstrated that a high level of SIL-2R before treatment is associated with both a low remission rate and poor prognosis [3] [4] [5] [6] [7] [8] .
SIL-2R is the soluble form of interleukin-2 receptor (IL-2R).
IL-2R is expressed on the cell membrane of lymphocytes and plays important roles in their activation and proliferation [9] . It is composed of at least three glycoprotein chains: a (55 kDa), b (75 kDa) and c (64 kDa). Each subunit is able to bind to the ligand independently with either low (IL-2Ra) or intermediate (IL-2Rb and c) affinity. It is now possible to examine the expression of the soluble-type a subunit [10] . The soluble IL-2Ra chain is induced and expressed only after mononuclear cell (T cell, B cell, monocyte, and natural killer cell) activation [11, 12] . Therefore, activated T and B cells have elevated levels of SIL-2R.
Although the CHOP regimen has been the mainstay of treatment for aggressive lymphomas for several decades [13] , treatment outcome has significantly improved with the introduction of rituximab (an anti-CD20 chimeric antibody) in both young and elderly patients [14] [15] [16] [17] . Since the introduction of rituximab, several prognostic factors have been reevaluated. Sehn et al. [18] recently reevaluated five prognostic factors and demonstrated that the IPI remained predictive; they proposed a revised IPI in which DLBCL patients are classified into very good (no IPI risk factors), good (one to two risk factors) and poor (three to five risk factors) categories. In contrast, BCL2, BCL6 and immunohistochemically defined germinal center (GC) phenotype have been reported to have no prognostic value when rituximab is added to chemotherapy [19] [20] [21] [22] [23] [24] . Other clinical factors or biomarkers identified in patients receiving CHOP therefore need to be reassessed in patients treated with CHOP combined with rituximab.
Up to now, the prognostic value of SIL-2R in RCHOP has not been investigated. The aim of the present study was to retrospectively reassess the prognostic value of SIL-2R in DLBCL patients receiving RCHOP as compared with CHOP alone and to investigate whether or not this factor still influences the outcome of DLBCL.
patients and methods

patient characteristics
In the present study, we reviewed the medical records of patients with CD20-positive DLBCL who received CHOP with or without rituximab as a first-line therapy at the Cancer Institute Hospital from January 2000 to December 2006 and were followed until January 2008. The study protocol and sampling were approved by the Institutional Review Board of the Cancer Institute Hospital. Informed consent for retrospective analysis and additional immunophenotypic analysis and gene rearrangement studies was obtained.
Patients were analyzed if they were older than 18 years and had a performance status (PS) of zero to three according to the criteria of the European Cooperative Oncology Group. Patients were excluded if they had clinically relevant cardiac diseases or positivity for antibodies against HIV-1 or 2. Patients with primary mediastinal large B-cell lymphoma, primary CNS lymphoma and primary testicular lymphoma were also not included in this study.
The disease stage was evaluated according to the Ann Arbor staging system. All patients had undergone staging investigations, including physical examinations, blood and serum analysis, bone marrow aspiration and biopsy and computed tomography of the neck, chest, abdomen and pelvis. Magnetic resonance imaging was used for evaluation of involved organs in the head and neck. The following clinical and laboratory data were available at the time of diagnosis: age, sex, serum lactate dehydrogenase level, PS, presence of B symptoms, clinical stage and number of extranodal sites. This allowed the IPI scores to be determined in the studied patients. Patients were categorized into either a low-risk group (IPI score, 0-2) or a high-risk group (IPI score, [3] [4] [5] . Response to initial therapy was evaluated according to the Cheson criteria [25] .
treatment
In both the CHOP and RCHOP groups, CHOP chemotherapy was given triweekly at a standard dose. Patients with stages IB-IV received six cycles, and patients with stage IA three cycles, of CHOP chemotherapy followed by radiotherapy for the involved field. After incorporation of rituximab into the CHOP regimen in February 2004, patients were treated with RCHOP regimen, in which rituximab was administered at a standard dose of 375 mg/m 2 once weekly for 8 weeks concurrently with triweekly CHOP, as described previously [26] .
chemical studies
The serum SIL-2R levels were determined using a sandwich enzyme-linked immunosorbent assay kit (Cell-free Interleukin-2 Receptor Test Kit, T Cell Science, Cambridge, MA) using two mAbs against distinct two different epitopes of the p55 alpha-chain of the IL-2R complex. Serum SIL-2R was considered 'high' when higher than the median and 'low' when lower than the median.
pathological studies
Biopsy samples collected before treatment were fixed in formalin, embedded in paraffin, sliced and stained with hematoxylin and eosin for morphological analysis. For diagnosis of DLBCL, immunohistochemical analysis was carried out using the dextran-polymer method (EnVision+; Dako, Glostrup, Denmark) with mAbs against CD5, CD10, CD20, Ki67, BCL2, BCL6 and MUM1 in most cases and with CyclinD1 to exclude the possibility of a pleomorphic variant of mantle cell lymphoma when the lymphoma was CD5 positive. Patients with a small-cell component implying transformation from low-grade/indolent B-cell lymphoma were excluded. All the samples were reviewed by an expert hematopathologist (KT).
statistical analysis
Basic characteristics of the CHOP group and RCHOP group were compared by Fisher's exact test. Event-free survival (EFS) was calculated from the date of diagnosis to the date of documented disease progression, relapse or death from any cause or to the stopping date. Overall survival (OS) was calculated from the date of diagnosis until death from any cause or the last follow-up. If the stopping date was not reached, the data were censored at the date of the last follow-up evaluation. Survival curves were estimated by the Kaplan-Meier method, and overall differences were compared by the log-rank test. Log-rank test was carried out according to SIL-2R, two-categorized IPI for the two treatment groups. To estimate the unbiased prognostic impacts of SIL-2R on EFS and OS, Cox proportional hazards analysis was applied. First, we conducted univariate Cox analysis for SIL-2L, all IPI factors and dichotomized IPI and then we carried out multivariate Cox analysis adjusted for SIL-2R and each of the IPI risk factors, with final adjustment for SIL-2R and dichotomized IPI. Only factors that were associated with at least a trend toward significance in the univariate analysis (unadjusted P value <0.20) were evaluated in the multivariate model. We set P <0.05 as the level of statistical significance. Data were analyzed using SPSS software version 11.0 for Windows (SPSS, Chicago, IL).
results patient characteristics
A total of 228 patients were analyzed, of whom 87 (38.2%) were given CHOP and 141 (61.8%) were given RCHOP. The median SIL-2R was 1005.5 mg/dl (range 220-35 600), and high SIL-2R was observed in 114 (50.0%) patients: 40 of 87 (46.0%) in the CHOP group and 74 of 141 (52.5%) in the RCHOP group. There was no significant difference in the proportion of high SIL-2R patients between the two treatment groups. The characteristics of the patients are listed in Table 1 . Patient and disease characteristics were well balanced between the groups.
survival analysis
With median follow-up periods of 30 months in the RCHOP group and 44 months in the CHOP group, EFS rates at 2 years were 78% and 65%, respectively (P = 0.030), and OS rates at 2 years were 89% and 81%, respectively (P = 0.040). For CHOP therapy, the EFS and OS rates at 2 years were 82% and 93% for low SIL-2R and 43% and 65% for high SIL-2R, respectively. The differences in both the EFS and OS rates between the two SIL-2R levels were significant (both P < 0.001) ( Figure 1A and B). In the RCHOP group, the EFS and OS rates at 2 years were 90% and 95% for low SIL-2R and 66% and 84% for high SIL-2R, respectively. The differences in both EFS and OS rates between the two SIL-2R levels were significant (EFS, P < 0.001; OS P = 0.005) ( Figure  1C and D) .
To study the impact of rituximab on the predictive value, we examined the clinical outcome according to treatment in the SIL-2R low and high groups. The patients with high SIL-2R who received RCHOP therapy had a significantly better OS at 2 years than patients treated with CHOP alone (84% versus 65%, P = 0.020). The EFS at 2 years was estimated to be 66% for the RCHOP group and 43% for the CHOP group (P = 0.010). For the patients with low SIL-2R, the influence of rituximab on OS and EFS was not significant (OS, 93% versus 95%, P = 0.310; EFS, 82% versus 90%, P = 0.160) ( Table 2) .
For comparison with this parameter, we analyzed the survival curves according to the IPI in both treatment groups. The EFS and OS rates at 2 years were 35% and 59% for high or highintermediate IPI and 77% and 91% for low or low-intermediate IPI, respectively, in the CHOP group. The differences in both EFS and OS rates between the two IPI groups were significant (both P < 0.001). Similarly, the EFS and OS rates were 58% and 80% for high or high-intermediate IPI and 86% and 94% for low or low-intermediate IPI, respectively, in the RCHOP group. Again, the differences in the EFS and OS rates were significant (P < 0.001 and P = 0.004, respectively).
To estimate unbiased prognostic impacts, Cox univariate analysis showed that a high SIL-2R level, high PS, advanced stage, multiple extranodal sites and high or high-intermediate risk of IPI were associated with poor EFS and OS in both treatment groups (Table 3 ). In the second step, Cox multivariate analysis showed that only SIL-2R was significantly associated with a higher risk of event and that SIL-2R and PS were independently associated with poor OS in both treatment groups (Table 4) . Finally, SIL-2R was a significant risk factor for EFS and a borderline risk factor for OS in both the CHOP and RCHOP groups (P = 0.060 and 0.070, respectively), whereas IPI was a significant risk factor for EFS and OS in the CHOP group and a borderline significant risk factor for EFS and OS (P = 0.070 and 0.080, respectively) in the RCHOP group (Table 5) .
discussion
Although SIL-2R is easy to measure, its prognostic value has been underestimated due to its evaluation in smaller populations than those for other parameters, such as IPI [2] . The SIL-2R level was reported to be significantly high in highly aggressive lymphomas [6] and subsequently was recognized to reflect tumor burden and poor outcome [3] [4] [5] [6] [7] [8] . However, these results were obtained in patients receiving chemotherapy, and the prognostic value of SIL-2R has not been assessed in rituximab-combined treatment.
In the present study, univariate analysis showed that SIL-2R retained its prognostic value in DLBCL patients treated with RCHOP, as well as in those receiving CHOP alone. Multivariate analysis also showed that SIL-2R was an independent significant prognostic factor after adjustment for IPI risk factors and independently associated with significantly decreased EFS and moderately decreased OS after adjustment by twocategorized IPI in both the CHOP and RCHOP groups. On the other hand, the clinical outcome of patients with high SIL-2R was significantly improved by addition of rituximab to the chemotherapy, in contrast to the lack of any difference in the patients with low SIL-2R. To our knowledge, this is the first report to demonstrate the prognostic value of SIL-2R in DLBCL patients treated with rituximab-combined chemotherapy.
Although the present study was not a randomized prospective one, and possibly biased by factors other than IPI and SIL-2R, the distribution of baseline characteristics, including IPI factors, was similar between the two treatment groups. On the other hand, the population employed in the present analysis had more limited disease and a favorable IPI score compared with those in previous studies of DLBCL [13] [14] [15] [16] [17] . This might account for the better outcome of our patients than for those in previous reports such as that by Coiffier et al. [14] who observed 2-year survival rates of 70% and 57% in elderly patients treated with RCHOP and CHOP, respectively. Even with the excellent outcome we observed, however, the prognostic value of SIL-2R was significant and greater than that of other IPI risk factors.
To allow our present results to be generalized to routine patient care, these findings should be validated in a variety of patient populations. A number of prognostic markers have been identified in patients with DLBCL treated by chemotherapy alone [19] [20] [21] , some of which have been reassessed and shown not to be associated with prognosis in patients receiving rituximabcombined chemotherapy [22] [23] [24] . BCL2 overexpression was reported to be associated with poorer survival in patients treated with CHOP-like regimens [19] , but its prognostic value was not confirmed in patients receiving rituximab-combined chemotherapy in several studies, indicating that addition of rituximab overcomes the negative influence of BCL2 [24] . BCL6, a marker of germinal center derivation, has been identified as an indicator of favorable outcome in DLBCL [20] , although outcome in patients receiving immunochemotherapy was reported to be uninfluenced by BCL6 status [22] . Similarly, no correlation between immunohistochemically defined GC phenotype and survival rate was observed in patients receiving immunochemotherapy [21] , in contrast to previous findings of inferior outcomes in non-GC patients relative to GC patients in the prerituximab era [23] . Up to now, no marker other than IPI has been found to be of prognostic relevance since the clinical introduction of rituximab. The mechanism by which rituximab added to chemotherapy improves outcome in relation to biological features has been evaluated in several studies. They showed that rituximab may suppress the constitutively active nuclear factor-kappa B pathway in non-GC phenotype DLBCL or downregulate Bcl-2-related antiapoptotic proteins, thereby increasing the sensitivity of lymphoma cells to chemotherapy [27] [28] [29] . These effects of rituximab may reduce the prognostic significance of the non-GC phenotype and BCL2. Although the mechanism by which SIL-2R retains its prognostic value after addition of rituximab to chemotherapy is unknown, SIL-2R may directly represent the tumor burden [7, 8] . To date, several studies including the present one have demonstrated that IPI score remains predictive in the rituximab era, in contrast to biomarkers [18, 22, 23] . In the present study, the IPI system identified only two risk groups instead of four among our patients-a low and lowintermediate group and a high and high-intermediate group-as reported in previous studies [22, 23] .
The addition of rituximab to chemotherapy has improved the outcome of patients. We and others have shown that OS now exceeds 50% even in the groups with unfavorable indicators [14-18, 22, 23] , although some patients still have a very poor outcome. Therefore, other predictive factors must be characterized in order to identify patients who should receive alternative initial therapy. A number of molecular prognostic markers have already been identified in patients with DLBCL [30] . These markers now need to be reevaluated in the rituximab era to identify patients with unfavorable prognostic factors and to devise adequate treatment strategies.
In conclusion, we have demonstrated that a high serum SIL-2R level is an indicator of poor prognosis in DLBCL patients receiving rituximab combination chemotherapy. To accurately confirm whether serum SIL-2R influences the outcome of patients receiving rituximab combination chemotherapy, prospective investigation with long-term follow-up will be required.
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